

Rīga

2014 year 30 may

## **JSC "Rīgas Farmaceutiskā Fabrika"**

Unaudited statement of financial position

for year **2014.**

**I quart.**

**CONTENTS**

	<b>Lpp.</b>
<b>Data of the enterprise</b>	<b>3</b>
<b>Governing body report</b>	<b>4</b>
<b>Statement of comprehensive income (profit and loss account)</b>	<b>5</b>
<b>Balance sheet :</b>	<b>6</b>
<b>- assets</b>	<b>6</b>
<b>- liabilities</b>	<b>7</b>
<b>Statement of cash flow</b>	<b>8</b>
<b>Overview of equity capital changes</b>	<b>9</b>
<b>Notes to the financial statement</b>	<b>10</b>

JSC "Rīgas Farmaceutiskā Fabrika" year 2014  
FINANCIAL REPORT

**DATA OF THE ENTERPRISE**

Full name of the enterprise	JSC "Rīgas Farmaceutiskā Fabrika"
The legal status of a society	Joint-stock company
The state registration in the register of the enterprises	registration Nr. 40003000765 , Riga , 1991 year 26 march
The legal address of the enterprise	Duntes street 16/22 , Riga , LV-1005
Main activity of the company	Manufacture of pharmaceutical preparations
NACE code	21.20
Members of the board	Kaspars BĀLIŅŠ Uģis FREIMANIS Dace KALEINE
Councillors	Dagmāra ĀBOLTIŅA Jūlija DMITRIJEVA Vladimirs IVANIKINS Natalja GORBUNOVA Aksana BĒRZIŅA
The accounting period	from <b>01.01.2014</b> to <b>31.03.2014</b>

**MANAGEMENT REPORT**

„Rīgas farmaceitiskā fabrika” JSC is located in Riga, 16/22 Duntes street and 6 Maza Ozolu street. The management of the company is realized by the Board of 3 persons.

The Company produce galenics products, therapeutically herbal teas and food supplies in Latvia. The factory was registered in the Register of Enterprises of the Republic of Latvia in 2004

The main types of operations of the company is the manufacturing of medicinal products, food supplies and medical goods. The finished products mainly were distributed in Latvia.

We have rebuilt our home page [www.rff.lv](http://www.rff.lv) starting this year. Our web page is modernized and made much more user-friendly and foreseeable. Here you can learn about all ongoing monthly special offers in local pharmacies chains, as well as get more depth information on each of our manufactured products. We have also started activities in different social networks- locals and internationals.

The neto turnover of the company in 3 mounth 2014 was **895 656 EUR** . The profit of the company in 2014 was **33 655 EUR** .

The management of joint stock company „Rīgas farmaceitiskā fabrika” is liable for the preparation of financial report and it is liable, that financial reports are prepared according to requirements of valid legislative acts and provides the true and clear conception about the assets, liabilities, financial situation and profit or losses, as well as for the fact that the management report includes true information.


The management of the company is liable about corresponding provision of bookkeeping system, the maintenance of the Company’s assets, as well as for the prevention and detection of the fraud and other irregularities in the Company. The management is also responsible for the accomplishment of Latvian legislation.



Kaspars BĀLINŠ



Uģis FREIMANIS



Dace KALEINE

---

---

2014 year 30 may

**STATEMENT OF COMPREHENSIVE INCOME for the period ended 31.03.2014**

		<b>2014.</b>	<b>2013.</b>
		<b>I quart.</b>	<b>I quart.</b>
		<b>EUR</b>	<b>EUR</b>
Net turnover	2	<b>895 656</b>	<b>484 340</b>
Cost of sales (prime cost)	3	-540 328	-235 793
<b>Gross profit or loss</b>		<b>355 328</b>	<b>248 547</b>
Sales distribution costs	4	-250 126	-172 243
Administration costs	5	-70 050	-43 953
Other operating income	6	63	1 696
Other operating expenses	7	-864	-9 906
Interest payable and similar charges	8	-696	-373
<b>Peļņa vai zaudējumi pirms ārkārtas posteņiem un nodokļiem</b>		<b>33 655</b>	<b>23 768</b>
Corporate income tax (postpone)		0	0
Other taxes	9	0	-498
<b>Profit or loss for the financial period</b>		<b>33 655</b>	<b>23 270</b>
<b>EPS k-t</b>		<b>0,0508</b>	<b>0,0351</b>

Annex from 10 . to 19 . is an integral part of these financial statements

  
Kaspars BĀLIŅŠ

  
Uģis FREIMANIS

  
Dace KALEĪNE

2014 year 30 may

JSC "Rīgas Farmaceutiskā Fabrika" year 2014  
FINANCIAL REPORT

**BALANCE SHEET for the period ended**

**31.03.2014**

**ASSETS**

		<b>2014.</b>	<b>2013.</b>
		<b>I quart.</b>	<b>I quart.</b>
		<b>EUR</b>	<b>EUR</b>
<b>Long - term investments</b>			
<b>Intangible investments</b>			
Concessions, patents, licenses, trade-marks and similar rights	10	5 531	20 916
Advance payments of intangible investments		0	0
<b>TOTALLY</b>		<b>5 531</b>	<b>20 916</b>
<b>Fixed assets</b>			
Lands, buildings, constructions and prenia plantations	11	420 421	440 345
Technological equipment and machines	11	53 831	117 740
Other fixed assets and inventory	11	53 446	25 394
Advance payments for fixed assets		0	0
<b>TOTALLY</b>		<b>527 698</b>	<b>583 479</b>
<b>Long - term investments   TOTALLY</b>		<b>533 229</b>	<b>604 395</b>
<b>Current assets</b>			
<b>Stocks</b>			
Raw materials, direct materials and auxiliary materials	12	551 592	341 984
Unfinished products	13	9 743	45 454
Complete products and goods for sale	14	160 060	202 917
Advance payments for goods		13 093	19 037
Work animals and productive animals	15	213	213
<b>TOTALLY</b>		<b>734 701</b>	<b>609 605</b>
<b>Debtors</b>			
Customers and client debts	16	168 484	71 751
Other debts	17	-81	414
Accured income	18	41 381	16 653
<b>TOTALLY</b>		<b>209 784</b>	<b>88 818</b>
<b>Cash assets</b>	19	3 261	6 160
<b>Current assets   TOTALLY</b>		<b>947 746</b>	<b>704 583</b>
<b>BALANCE</b>		<b>1 480 975</b>	<b>1 308 978</b>

**BALANCE SHEET for the period ended 31.03.2014**

<b>LIABILITIES</b>		<b>2014.</b>	<b>2013.</b>
		<b>I quart.</b>	<b>I quart.</b>
		<b>EUR</b>	<b>EUR</b>
<b>Equity capital</b>			
Stock or share capital (equity capital)	20	943 364	943 364
Retained profit:			
a) Retained profit of previous years		-11 833	-48 924
b) Retained profit of the year of accountant	21	33 655	23 270
<b>TOTALLY</b>		<b>965 186</b>	<b>917 710</b>
<b>Stockpiles</b>			
Other stockpiles	22	33 144	29 506
<b>TOTALLY</b>		<b>33 144</b>	<b>29 506</b>
<b>Creditors</b>			
<b>Long - term debts</b>			
Other loans	23	144 531	35 704
Tax on profit (pustpone) or loss for the financial period	27	0	0
<b>TOTALLY</b>		<b>144 531</b>	<b>35 704</b>
<b>Short - term debts</b>			
Other loans	23	29 461	20 696
Debts to suppliers and contractors	24	228 021	195 268
Tax and social security payments	25	57 860	30 849
Other creditors	26	22 772	18 347
Accrued liabilities	28	0	60 898
<b>TOTALLY</b>		<b>338 114</b>	<b>326 058</b>
<b>Creditors TOTALLY</b>		<b>482 645</b>	<b>361 762</b>
<b>BALANCE</b>		<b>1 480 975</b>	<b>1 308 978</b>

Annex from 10. to 19. is an integral part of these financial statements

  
Kaspars BĀLINŠ

2014 year 30 may


  
Uģis FREIMANIS

  
\_\_\_\_\_

**STATEMENT OF CASH FLOW for the period ended 31.03.2014**  
**(indirect method)**

	<b>2014.</b> <b>I quart.</b> <b>EUR</b>	<b>2013.</b> <b>I quart.</b> <b>EUR</b>
<b>CASH FLOW from operating activities</b>		
<b>Profit or loss before extraordinary items and tax</b>	<b>33 655</b>	<b>23 768</b>
Corrections :		
depreciation of fixed assets and intangible investments (+)	130 870	40 089
accumulation for unused vacation (+)	0	0
interest payable and similar charges (+)	696	373
<b>Profit or loss before working capital and working capital correction influence</b>	<b>165 221</b>	<b>64 230</b>
Corrections :		
debts of customers and subscribers	-114 285	14 757
provisions	185 352	-171 846
others debtors	-223 996	107 036
<b>Net cash provided by operating activities</b>	<b>12 292</b>	<b>14 177</b>
interest payments (-)	696	-373
the taxes deducted from net profit (property tax)	0	-499
<b>Cash flow from operating activities</b>	<b>12 988</b>	<b>13 305</b>
<b>Investing activities</b>		
fixed assets purchase costs	-23 910	-3 530
income from sale of fixed assets	0	0
<b>Cash provided by investing activities</b>	<b>-23 910</b>	<b>-3 530</b>
<b>Cash flow from financing</b>		
received loans	27 360	0
Expenses of leased fixed assets (-)	-14 926	-6 861
<b>Net financing cash flow</b>	<b>12 434</b>	<b>-6 861</b>
<b>Net increase (decrease) in cash</b>	<b>1 512</b>	<b>2 914</b>
<b>Cash at the beginning of the year</b>	<b>1 749</b>	<b>3 246</b>
<b>Cash at the end of the year</b>	<b>3 261</b>	<b>6 160</b>

Annex from 10. to 19. is an integral part of these financial statements



Kaspars BĀLINŠ



Uģis FREIMANIS



Dace KALEINE

2014 year 30 may



JSC "Rīgas Farmaceutiskā Fabrika" year 2014  
FINANCIAL REPORT

**OVERVIEW of EQUITY CAPITAL CHANGES**  
**for the period ended 31.03.2014**

	Share capital	Reserves	Retained profit of previous years	Retained profit of the year of accountant	Equity capital (total)
	EUR	EUR	EUR	EUR	EUR
<b>31.12.2012</b>	<b>943 364</b>	<b>0</b>	<b>-83 097</b>	<b>34 173</b>	<b>894 440</b>
2012 year profit transferred to retained earnings			34 173	-34 173	-
Retained profit of the year of accountant				37 091	37 091
Relief for losses from reserves					-
<b>31.12.2013</b>	<b>943 364</b>	<b>-</b>	<b>-48 924</b>	<b>37 091</b>	<b>931 531</b>
2013 year profit transferred to retained earnings			37 091	-37 091	-
Retained profit of the year of accountant				33 655	33 655
<b>31.03.2014</b>	<b>943 364</b>	<b>-</b>	<b>-11 833</b>	<b>33 655</b>	<b>965 186</b>

Annex from 10. līdz 10. to 19. is an integral part of these financial statements




Kaspars BĀLINŠ

2014 year 30 may



Uģis FREĪMANIS



Dace KALEINE

## (1) STATEMENT OF ACCOUNTING POLICIES - GENERAL PRINCIPLES

### **Basis of preparation**

The Annual Report is prepared in accordance with Latvian law "On Accounting" and "Annual reports".

The income statement is prepared in accordance with the turnover method.

The cash flow statement prepared using the indirect method.

### **Net sales**

Net sales represent the revenues of the company's core business, the sale of products and services, net of trade discount and other discounts granted, as well as value added tax and other taxes directly related to the sale.

Proceeds from the sale of goods is recognized when the buyer s accepted the goods, according to delivery terms.

### **During the reporting period**

The reporting period is 3 months of 01.01.2014 to 31.03.2014 .

### **Currency and foreign currency translation**

These financial statements are expressed in the Latvian national currency - euro (EUR).

All monetary assets and liabilities are translated into Latvian lats at the exchange rate at the period end.

Foreign exchange rate fluctuations on profit or loss is reflected in the profit and loss account.

### **Long-term and short-term items**

Long-term items of an amount reported by the receipt, payment, or write-off shall be the later of one year after the year end.

The amounts received, paid or written off during the reported short-term positions.

### **Non-current assets and depreciation recognition**

Balance sheet of all fixed assets and intangible assets are stated at cost less depreciation rates.

Depreciation is calculated on straight-line methods,

choosing on the basis of the following rates:

#### *Intangible assets:*

license	<u>20</u>	%
other intangible assets	<u>20</u>	%

#### *Fixed Assets:*

Buildings and structures	<u>5-10</u>	%
Iekārtas un mašīnas		%

Язык оригинала: английский

Введите текст или адрес веб-сайта либо переведите документ.

Отмена

латышскийанглийскийрусскийAlpha

Equipment and machinery	<u>20</u>	
Other fixed assets	<u>20-35</u>	%

AS "Rīgas Farmaceutiskā Fabrika" year 2014  
FINANCIAL REPORT

**Measurement of inventories**

Reserves are estimated using FIFO method.  
Inventory balances checked on the inventory.

**Receivables**

Trade receivables are shown net of.

**Savings**

Provisions are intended to cover certain types of obligations, relating to the reporting year or previous years and Annual Reports of the anticipated or known, but the amount or specific commitment to the creation or the date of recovery is uncertain.

**Provision for vacation pay**

Amount of the provision is determined by multiplying the average employee salary of one day to the year-end accrued but unused vacation days.

**Accrued liabilities**

Clearly aware of the settlement amount payable for the current year goods or services received if the balance sheet date has not yet received the corresponding payment document in accordance with the supply, sale or contract business conditions or other reasons, recognized as accruals for the period.

**Corporate income tax**

Corporate income tax costs are included in the financial statements in accordance with Latvian tax legislation of.

For the reporting period the estimated tax is calculated under the Law "On Corporate Income Tax " 'claims in determining taxable income, and applying the statutory tax rate of 15%.

JSC "Rīgas Farmaceutiskā Fabrika" year 2014  
FINANCIAL REPORT

**(2) Net Sales**

Type of activity	2014.	2013.
	EUR	EUR
Manufacture of drugs	874 055	462 927
Raw materials and distribution	7 977	7 422
Provision of services	13 624	13 991
<b>Total</b>	<b>895 656</b>	<b>484 340</b>

**Net sales by geographical markets**

State	2014.	2013.
	EUR	EUR
Latvia	847 129	434 530
Lithuania	3 097	7 674
Estonia	45 430	42 136
Other	0	0
<b>Total</b>	<b>895 656</b>	<b>484 340</b>

**(3) Cost of sales**

	2014.	2013.
	EUR	EUR
Cost of materials	338 110	66 239
Staff costs	72 742	38 395
State social security contributions	22 658	9 017
Depreciation of fixed assets and intangible assets depreciation	28 175	40 089
Depreciation of current assets	1 227	1 387
Maintenance costs	48 041	47 254
Transport costs	16 141	11 932
Other	13 234	21 480
<b>Total</b>	<b>540 328</b>	<b>235 793</b>

**(4) Sales expenses**

	2014.	2013.
	EUR	EUR
Staff costs	107 721	67 529
State social security contributions	25 853	15 686
Advertising expenses	92 281	85 206
Transport costs	5 452	2 456
Other	18 819	1 366
<b>Total</b>	<b>250 126</b>	<b>172 243</b>

JSC "Rīgas Farmaceutiskā Fabrika" year 2014  
FINANCIAL REPORT

**(5) Administration costs**

	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
Staff costs	33 691	20 034
State social security contributions	7 655	4 799
Legal and accounting services	4 475	1 431
Transport costs	8 596	3 460
Other	15 633	14 229
<b>Total</b>	<b>70 050</b>	<b>43 953</b>

**(6) Other operating income**

	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
The difference of exchange rate changes and currency sales	63	159
Received a penalty	0	750
Proceeds from sale of fixed assets	0	0
Other	0	787
<b>Total</b>	<b>63</b>	<b>1 696</b>

**(7) Other operating expenses**

	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
Expenses not related to economic activity	412	9 237
The difference of exchange rate changes and currency sales	118	0
Penalties	6	28
Gifts and benefits	0	213
Other	328	428
<b>Total</b>	<b>864</b>	<b>9 906</b>

**(8) Interest payable and similar charges**

	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
Leasing interest payments	696	373
<b>Total</b>	<b>696</b>	<b>373</b>

**(9) Other taxes**

	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
Real estates tax	0	498
<b>Total</b>	<b>0</b>	<b>498</b>

## (9) Intangible assets

	Licenses and patents	Advance payment for intangible assets	Total intangible assets
	EUR	LVL	EUR
Historical cost as of <b>31.12.2013</b>	141 458	0	141 458
Additions	0	0	0
Disposals	0	0	0
<b>31.03.2014</b>	141 458	0	141 458
Accumulated depreciation before <b>31.12.2013</b>	131 784	0	131 784
Accumulated depreciation	4 143	0	4 143
<b>31.03.2014</b>	135 927	0	135 927
<b>Net book value 31.12.2013</b>	9 674	0	9 674
<b>Net book value 31.03.2014</b>	5 531	0	5 531

JSC "Rīgas Farmaceutiskā Fabrika" year 2014  
FINANCIAL REPORT

**(11) Fixed assets**

	Land and buildings	Equipment	Other fixed assets	Advance payment for fixed assets	Fixed assets total
	EUR	EUR	EUR	EUR	EUR
<b>Historical cost as of</b>					
<b>31.12.2013</b>	<b>1 016 266</b>	<b>822 438</b>	<b>400 678</b>	-	<b>2 239 382</b>
Additions	0	0	23 910	0	23 910
Disposals	0	0	0	0	0
<b>31.03.2014</b>	<b>1 016 266</b>	<b>822 438</b>	<b>424 588</b>	<b>0</b>	<b>2 263 292</b>
Accumulated depreciation before					
<b>31.12.2013</b>	<b>526 142</b>	<b>749 300</b>	<b>332 034</b>	-	<b>1 607 476</b>
Accumulated depreciation	69 703	19 307	39 108	0	128 118
Excluded on disposal	0	0	0	0	0
<b>31.03.2014</b>	<b>595 845</b>	<b>768 607</b>	<b>371 142</b>	<b>0</b>	<b>1 735 594</b>
<b>Net book value 31.12.2013</b>	<b>490 124</b>	<b>73 138</b>	<b>68 644</b>	<b>0</b>	<b>631 906</b>
<b>Net book value 31.03.2014</b>	<b>420 421</b>	<b>53 831</b>	<b>53 446</b>	<b>0</b>	<b>527 698</b>

**(12) Raw materials, direct materials and auxiliary materials**

	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
Materials	241 853	169 113
Consumables - glass containers	141 840	73 762
Consumables - plastic and metal packages	37 932	68 201
Printed materials	98 829	18 254
Other	31 138	12 654
<b>Total</b>	<b>551 592</b>	<b>341 984</b>

**(13) Unfinished products**

	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
The packing station neizfasēta products (quarantine area)	7 003	29 885
Production units of semi-finished products segment	2 740	15 569
<b>Total</b>	<b>9 743</b>	<b>45 454</b>

**(14) Complete products and goods for sale**

	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
The company's stock of finished goods in stock	160 060	202 917
<b>Total</b>	<b>160 060</b>	<b>202 917</b>

**(15) Work animals and productive animals**

	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
Guard dogs	213	213
<b>Total</b>	<b>213</b>	<b>213</b>

**(16) Customers and client debts**

	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
Trade receivables have a carrying amount	168 484	71 751
<b>Book value</b>	<b>168 484</b>	<b>71 751</b>

By currencies :

	<b>2014.</b>	<b>2013.</b>
	<b>currency</b>	<b>EUR</b>
EUR	168 484	71 751
Other	0	0
<b>Total</b>	<b>168 484</b>	<b>71 751</b>



JSC "Rīgas Farmaceutiskā Fabrika" year 2014  
FINANCIAL REPORT

**(17) Other debts**

	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
Tax receivables together	0	0
Operatīvā līzīngā neamortizētās daļas of settlement balances	-81	414
<b>Total</b>	<b>-81</b>	<b>414</b>

**(18) Accrued income**

	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
Property Insurance	4 522	6 434
Vehicle Insurance	629	895
Employee Health Insurance	10 263	8 453
Magazine subscription	264	376
Other	25 703	495
<b>Total</b>	<b>41 381</b>	<b>16 653</b>

**(19) Cash Assets and EUR currency according to the 31.12.**

By currencies :	<b>2014.</b>		<b>2013.</b>	
	<b>currency</b>	<b>EUR</b>	<b>EUR</b>	
EUR		3 261	6 160	
Other		0	0	
<b>Total</b>		<b>3 261</b>	<b>6 160</b>	

JSC "Rīgas Farmaceutiskā Fabrika" year 2014  
FINANCIAL REPORT

**(20) Share capital**

	943 364	EUR
consisting of	<u>660 000</u>	ordinary shares with voting rights
and	<u>3 000</u>	common shares without voting rights
Each share is LVL	<u>1,423</u>	

**(21) Retained earnings**

	<b>EUR</b>
For 2013. the reporting year, the profits up	<b>33 655</b>

**(22) Other provisions**

	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
Provision for unused vacations	33 144	29 506
<b>Total</b>	<b><u>33 144</u></b>	<b><u>29 506</u></b>

**Long-term debts**

	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
<b>(23) Other loans</b>	144 531	35 704
<b>Total</b>	<b><u>144 531</u></b>	<b><u>35 704</u></b>

**Short-term debts**

	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
<b>(23) Other loans</b>	29 461	20 696
<b>Total</b>	<b><u>29 461</u></b>	<b><u>20 696</u></b>

	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
<b>(27) Tax on profit (pustpone) or loss for the financial period</b>	0	0
<b>Total</b>	<b><u>0</u></b>	<b><u>0</u></b>

**(24) Trade and other payables**

<b>Current portion of</b>	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
Trade and other payables the carrying amount of	228 021	195 268
<b>Total</b>	<b><u>228 021</u></b>	<b><u>195 268</u></b>

<b>Current portion of</b>	<b>2014.</b>		
<b>By currencies :</b>	<b>currency</b>	<b>EUR</b>	<b>EUR</b>
EUR	228 021	228 021	195 268
Other	0	0	0
<b>Total</b>	<b><u>228 021</u></b>		<b><u>195 268</u></b>

JSC "Rīgas Farmaceutiskā Fabrika" year 2014  
FINANCIAL REPORT

<b>(25) Current portion of</b>	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
Corporate income tax	0	0
Value-added tax	30 703	8 394
State social security contributions	17 005	14 142
Personal income tax	9 954	8 089
Business risk charge	22	23
Natural resource tax	176	201
Nekustamā īpašuma nodoklis	0	0
<b>Total</b>	<b>57 860</b>	<b>30 849</b>

<b>(26) Current portion of</b>	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
Wage debt	22 772	18 347
<b>Total</b>	<b>22 772</b>	<b>18 347</b>

<b>(28) Accrued liabilities</b>	<b>2014.</b>	<b>2013.</b>
	<b>EUR</b>	<b>EUR</b>
Accrued discounts will be	0	56 914
Other	0	3 984
<b>Total</b>	<b>0</b>	<b>60 898</b>

<b>(29) Number of employees</b>	<b>2014.</b>	<b>2013.</b>
	The average number of persons employed by the company	67

**(30) News about events after the balance sheet date**

In the period since the last days before the reporting date is no significant events that could materially affect the results of the annual report.